Category: CannabisNewsWire Release

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Quest to Find Hypertension Treatment Promising With DehydraTECH(TM)’s Ability to Boost Bioavailability

  • Lexaria, a global innovator of drug delivery platforms is looking to provide a FDA registered hypertension treatment with its patented DehydraTECH technology
  • The company’s efforts are encapsulated in its DehydraTECH-CBD that has been shown to lower blood pressure as well as reduce arterial stiffness
  • Although hypertension is a devastating condition that can cause not only life-threatening illnesses but also death, only about 53% of Americans with the condition have it under control
  • A Harvard Health article notes that the remaining portion (47%) are not able to control the disease because they are discouraged by medications’ side effects
  • Lexaria’s DehydraTECH-CBD may well be the solution such individuals seek, but for now, the company is following the regulatory pathway to eventual drug approval

Hypertension causes life-threatening conditions such as stroke, heart attacks, coronary artery disease, and heart failure. But even more concerning, the condition leads to death. In 2020, the U.S. Center for Disease Control (“CDC”) reported that high blood pressure claimed more than 670,000 lives in the U.S. (https://cnw.fm/1PKhk). Globally, hypertension claims an estimated 7.5 million lives annually, according to the World Health Organization (“WHO”) (https://cnw.fm/UCJeh).

Despite these devastating consequences and statistics, only about half (53%) of Americans living with high blood pressure have it under control, a problem that a Harvard Health article attributes to, among other common reasons, the fact that many stop taking their medication citing side effects (https://cnw.fm/PyIVN).

As a result, scientists and researchers have continuously explored ways to increase the chances of success as regards having the condition under control. One such study, a clinical trial, employed “a new strategy where patients are started on a pill containing four medicines, each at a quarter of their usual doses. [The strategy] has been shown to be much more effective in getting blood pressure under control, compared to the common practice of monotherapy, where treatment commences with just one drug” (https://cnw.fm/hIzEK).

For researchers and scientists at Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, their quest takes a different approach that combines the effectiveness of the company’s proprietary DehydraTECH(TM) drug delivery technology and the emerging benefits of cannabidiol (“CBD”), one of which is the substance’s ability to slow down the heart rate and blood pressure, particularly in stressful situations (https://cnw.fm/3zQRf). In the latest tests, DehydraTECH-CBD has undergone human evaluations, yielding promising results.

CBD lowers systolic blood pressure in isolation (https://cnw.fm/bmz4O). However, with the addition of DehydraTECH, its capability and performance are boosted even further (https://cnw.fm/i311C). This is chiefly because DehydraTECH increases CBD’s bioavailability, a term that refers to the percentage of a drug that enters the bloodstream and becomes available to the intended biological target. In its first human study, conducted in 2018 and involving 12 patients, Lexaria showed that DehydraTECH delivered 317% more CBD to the bloodstream 30 minutes after ingestion (https://cnw.fm/E8e8K).

Since then, the company has undertaken a series of other human studies. 2021, in particular, saw the company complete three studies: HYPER-H21-1, HYPER-H21-2, and HYPER-H21-3. The first study evidenced a rapid and sustained decrease in blood pressure, particularly systolic pressure. The second study showed that DehydraTECH-CBD caused a 23% average reduction in overnight blood pressure in addition to reducing arterial stiffness. The third revealed that the substance caused a 41% overall attenuation in pulmonary artery systolic pressure among male participants.

Its fourth study, HYPER-H21-4, is its most comprehensive yet. With dosing having been completed in late July, Lexaria announced that no serious adverse events were reported. “Demonstrating a noteworthy safety and tolerability profile relative to conventional anti-hypertensive medications is one of Lexaria’s major goals with this program, and avoiding serious adverse events at clinically efficacious doses will be a primary requirement to achieve eventual regulatory marketing authorization,” Lexaria CEO Chris Bunka said of the HYPER-H21-4 study (https://cnw.fm/qqtZb).

The company looks to leverage the results of the fourth study to file an Investigational New Drug (“IND”) application seeking the U.S. Food and Drug Administration (“FDA”)’s approval to begin registered clinical testing at Phase I level or higher. The study, Lexaria observes, is designed to boost the company’s probability of success with the application.

And as analysis contained in an August 11 press release shows, the commencement of Phase I (or even higher) studies, as and when it happens, could portend good tidings for the company’s investors. According to a valuation guide authored by Bay Bridge Bio, the potential valuation of a company increases as a company’s clinical trials move from Phase I through Phase III. Accordingly, Lexaria’s valuation may trend upward with time (https://cnw.fm/mjpxT).

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Improvements in Marijuana Genetics Boosting Profits, Protecting the Environment

Despite the medical and economic benefits that come with cannabis reform, marijuana cultivation can be extremely hard on the environment. Cultivating the substance requires a ton of energy for heating and cooling, consumes gallons upon gallons of water, and is often associated with an increased number of airborne pollutants. Furthermore, the pesticides used to keep pests and diseases away from cannabis grows can leach into the ground and contaminate the soil.

With the cannabis industry poised to be worth $197.74 billion by 2028, regulators and stakeholders are looking for ways to reduce the environmental impact of cannabis cultivation. Improving marijuana genetics has emerged as a means of not only protecting the environment but also increasing profits within the nascent cannabis industry.

Thanks to advances in technology and science, it is now possible for cultivars to tweak cannabis genetics and make them more resistant to fungus and common pests, ultimately reducing cultivation inputs and increasing yields.

Although the illicit market has made significant advancements in increasing cannabis potency, little has been done to make cannabis more resistant to pests and fungi. As a result, growers have to practice extreme vigilance and invest in expensive pesticides, which could contaminate the end product and damage the environment.

Fortunately, the industry is becoming home to cleaner cannabis products, both in terms of product quality and environmental impact, due to new research and scientific breakthroughs that are aimed at eliminating the use of dangerous chemicals in the management of pests and diseases.

Improvements in cannabis genetics will make marijuana plants more resistant to pests and diseases. This will in turn reduce the number of pesticides and fungicides growers use on their plants and limit pesticide and fungicide contamination that impact consumers and the environment.

These advancements will also make plants hardier, meaning growers will be less likely to lose their entire crop due to pest and disease infestation or pesticide contamination. Companies will also spend less on staff to constantly monitor the plants, a cost that can be prohibitively expensive depending on the size of the operation.

Cumulatively, the result will be pest- and disease-resistant cannabis plants that are more likely to produce higher yields, thereby also producing higher profits while also reducing employee costs, which increases profit margins even further. Additionally, these advancements in marijuana genetics will reduce the impact of cannabis cultivation on the environment by reducing fertilizer and pesticide use.

Researchers will also be able to develop cannabis genetics that can function in different climates, a feat that will allow growers to stay profitable as the climate becomes increasingly unpredictable.

This stability is critical if established industry companies such as Flora Growth Corp. (NASDAQ: FLGC) are to keep their products competitively priced and attract even more consumers at a time when costs of production are spiraling around the world.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Research into Medical Benefits of Marijuana Is Growing

Decades of federal prohibition, intense policing and harsh sentencing made it virtually impossible for researchers to study the possible effects and risks of cannabis consumption. But over the past 20 years or so, loosening marijuana policies across the country have made it possible for scientists to finally study cannabis. Anecdotal reports coupled with initial studies have revealed that cannabis has plenty of medical potential, leading to a slew of states legalizing medical cannabis.

More than 25 years after California first legalized medical cannabis, researchers are still delving into the controversial plant. There’s still a lot that we don’t know about cannabis, including how long-term consumption can affect users; this is primarily due to restrictions placed on cannabis research by the federal government.

Most of our scientific data on cannabis comes from a handful of studies that were mostly carried out by pharmaceutical companies, universities and other entities, with a significant percentage of the funding for these studies coming from the National Institutes of Health and the National Institute on Drug Abuse.

In recent months, however, the U.S. Drug Enforcement Administration (DEA) has expanded the number of entities that are federally allowed to research cannabis from one to six. The DEA has also issued cannabis research licenses to entities interested in delving deeper into marijuana’s properties and effects and has even awarded licenses to companies with state-level marijuana retail licenses, including MedPharma Holdings in Colorado.

The cannabis research field has also seen a slight increase in federal funding opportunities, with one Connecticut-based firm, CT Pharma,  managing to snag federal approval for a partnership that would see it supply cannabis to Yale University for research purposes. The segment is also expected to see an infusion of federal funding due to a provision in last year’s $1 trillion federal infrastructure bill, which allows researchers to use cannabis from state-licensed retail businesses in their studies.

Surprisingly, plenty of federally sanctioned marijuana growers and researchers say that the Food and Drug Administration (FDA) has been quite supportive. In a prior interview with MJBizDaily, MedPharma CEO Albert Gutierrez said that working with the DEA has been quite good, stating that while the federal agencies can be slow, they are responsive. Scottsdale Research Institute’s Dr. Sue Sisley also noted the company’s great working relationship with the DEA, saying that the agency has been a collaborative supporter in the decade and a half since it began working with the institute.

Attitudes in the scientific, medical and pharmaceutical industries are shifting in favor of cannabis research, with millions of dollars being invested in medical marijuana research. There are an increasing number of studies looking into cannabis’ impact on ailments such as sleep problems, brain inflammation, opiate replacement and pain management. We can expect to see even more cannabis research in the coming years if lawmakers pass federal cannabis legislation and remove the existing restrictions on research.

As those restrictions are eased, it could get a little easier for sector players such as American Cannabis Partners to conduct the requisite research in the course of coming up with innovative products to suit the changing dynamics of the marijuana market.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced an addition to its board of directors; the company named industry veteran Catherine Turkel, PharmD, PhD, as the newest member of its board. Turkel brings more than two decades of experience as an executive-level leader in both start-up and mid-size pharma/biotech companies. As founder and CEO of Nezee Therapeutics, she gained critical expertise and insight in the space; she also served as president and head of research and development Novus Therapeutics, which was later renamed Eledon Pharmaceuticals Inc. (NASDAQ: ELDN). Currently she serves as an independent board director at Object Pharma and advisory committee member at nonprofit Prostate Cancer Research; she is also a dean advisor at Chapman University School of Pharmacy. In her various roles, Turkey has led and executed FDA registration and commercial strategic plans as well as global development programs; she has invaluable experience in a range of sectors, including neurosciences, pain, cardiovascular, psychiatry, rare diseases, ophthalmology, aesthetics, urology and otology therapeutic areas. In addition, Turkel designed and led an innovative BOTOX(R) chronic migraine registration program for Allergan, now AbbVie Inc. (NYSE: ABBV), which generated more than a billion dollars. “Lexaria is delighted to welcome Dr. Turkel as we continue to position the company for advancement following our recent successful pre-IND meeting with the Food and Drug Administration,” said Lexaria board chair Chris Bunka in the press release. “Catherine’s practical development and regulatory expertise will be of increasing value to Lexaria, and we look forward to working with her.”

To view the full press release, visit https://cnw.fm/JroKp

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com. 

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — FBI Reveals That CBD Users Are Disqualified from Working at Agency

Last week, the FBI stated that the recent use of cannabis and components such as CBD automatically disqualified individuals from working at the agency. In a response to a question raised on Twitter, FBI Denver explained that while the use of CBD and cannabis was legal at the state level, their use was a disqualifier for  contractors and employees looking to work with the agency.

The handle went on to explain that individuals needed to wait at least a year from when they last used the substances before they applied to the federal agency. This is despite the fact that under the 2018 farm bill, hemp and derivatives such as CBD are federally legal.

In 2020, a separate field office stated that the agency’s employment policies for CBD were under review. Despite this, the FBI is yet to issue any new guidance that addresses CBD, which is widely available in many commercial markets across America.

A year later, the agency loosened its marijuana employment policy, making it so that individuals need only wait a year instead of three years before applying for a job at the agency. This new guidance was revised to omit a policy that restricted an individual’s eligibility based on the number of times they had consumed marijuana.

The earlier version stipulated that the use of cannabis or any of its forms, whether natural or synthetic, in any location regardless of its legality, more than 24 times after an individual had turned 18 disqualified them from employment at the agency.

While FBI candidates aren’t forbidden from using synthetic marijuana drugs approved by the FDA, the agency stresses that candidates can’t present prescriptions or medical cannabis cards as mitigating factors for cannabis or marijuana use.

Federal agencies have taken different approaches to marijuana employment policies as the legalization movement spreads across states in the country. For instance, the biggest union in the country, which represents federal employees, recently adopted an initiative supporting the legalization of marijuana. The union also called for the  end to policies that penalized federal workers who used marijuana responsibly after working hours in states where it was legal to be done away with.

Additionally, the Environment Protection Agency has highlighted that the use of marijuana by their workers is still prohibited. Its workers are also not allowed to directly invest in the marijuana industry.

In addition to this, the U.S. Forest Service recently posted a notice warning employees about the risks of consuming CBD products that were federally unregulated, noting that they were prohibited from using marijuana.

It is these contradictions between federal and state cannabis laws that create a complex environment for entities such as Advanced Container Technologies Inc. (OTC: ACTX) to operate and thrive.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Two Marijuana Policy Reform Bills Sent to California Governor’s Desk

California has been a pioneer in America’s cannabis industry. Among the first states to legalize recreational cannabis, California now generates billions of dollars in marijuana sales and is home to one of the largest cannabis industries in the world. As the end of the legislative season approaches, a slew of cannabis legislations have passed through the legislature.

Lawmakers have managed to pass several major cannabis bills, including ones that would enable interstate commerce, make the sealing of marijuana convictions more streamlined, and provide protections for insurance companies that serve the cannabis industry past; these bills are headed to Governor Gavin Newsom’s desk. There are still several other cannabis bills that haven’t made it that far, such as a bill that would provide job protections for people who consume cannabis on personal time and one that would bar local governments from prohibiting medical marijuana deliveries.

Two major cannabis bills that reached Newsom’s desk are SB 1326, introduced by Senator Anna Callabero, and AB 1706, introduced by Assemblymember Mia Bonta. If it is signed into law, SB 1326 would set up a framework for interstate cannabis commerce, allowing for trade between California’s cannabis industry and markets in other legal states. According to the bill, interstate marijuana commerce will be reliant on an official assurance that the trade does not put the state at risk of federal retaliation.

Coincidentally, New Jersey Senate president introduced legislation that would facilitate interstate cannabis commerce under similar conditions the same week that SB 1326 went through the Assembly Appropriations Committee. SB 1326 then advanced through the full chamber before the Senate approved it via a 298 to 9 vote.

AB 1706 is meant to bolster state law-mandated cannabis justice provisions by streamlining the record sealing process for prior cannabis convictions. The legislation would require courts to process cannabis conviction record sealing and other kinds of relief for eligible people with cannabis convictions within a set timeframe. More specifically, AB 1706 will give courts until March 1, 2023, to seal records for qualifying cannabis cases that had not been challenged by July 1, 2020.

After Senate amendments that changed record sealing reporting requirements from monthly to quarterly, AB 1706 advanced past the full chamber and then headed to the assembly where it was unanimously approved. Another bill — AB 2568 — was introduced by Assembly member Ken Cooley and would provide legal protections for companies that provide insurance-related services to businesses in the cannabis industry. All three bills, alongside bill AB 1954, which would protect patients who use medical cannabis, now await the governor’s signature.

Once these bills are signed into law and become operational, the regulatory environment in which companies such as Prime Harvest Inc. interact will be tad bit friendlier to the industry.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — How Marijuana Retailers Can Minimize Budtender Turnover

The American cannabis industry has been one of the most prolific job creators in recent times, creating hundreds of thousands of new jobs and generating billions of dollars in sales revenue. Of the entire class of cannabis employees, budtenders are probably the most recognized among cannabis users. This position interacts with customers the most, answering questions about different marijuana strains, medical applications and optimum methods of consumption.

However, the retail cannabis space is currently plagued by a high turnover of budtenders, an issue that could severely affect the industry in the long term. As the front face of cannabis retail stores, budtenders are usually the first point of contact between the customer and the business. To ensure that these individuals convey accurate and up-to-date information to customers, brands and cultivators invest significant amounts of money and time into training and educating budtenders about the products they offer.

The problem is that many budtenders leave soon after receiving this training, costing the companies that initially hired them cash as well as depriving them of much-needed expertise. The president of a California-based cannabis cultivator called Ember Valley says marijuana operators often spend time and resources building relationships with budtenders and similar employees who are on the front lines with the customer, only for them to leave.

A recent report from analytics firm Headset revealed that 55% of budtenders in the United States and Canada who had worked at a retail cannabis establishment in the past year had left “by the end of that time period.” Greenleaf Business Solutions president Mar Rodriguez posits that players in the cannabis sector have to legitimize the employee experience if they wish to retain budtenders.

Thanks to federal prohibition, the state-legal cannabis industry cannot access traditional banking services. This means that many employees in the sector are paid in cash, and many cannabis employers still don’t offer 401(k) plans or online pay stubs. Companies that offer these benefits in the cannabis space are few, Rodriguez says, and accessing these types of financial and banking services tends to be more costly for cannabis businesses compared to other industries.

On average, he estimates, cannabis businesses spend an extra $60,000 annually on payroll and employee services. For companies that simply can’t afford to offer these services, retaining employees can be a challenge. FutureSense CEO Jim Finkelstein believes that good leadership also plays a role in retaining employees, stating that the number-one reason people leave their jobs is because of poor leadership or not being provided enough tools to advance their skill sets.

Finkelstein says that even though companies can plan for high employee turnover by implementing a business strategy called “come, contribute, leave,” this strategy will hurt them in the long term, resulting in increased hiring costs and depriving companies of much-needed labor as well as raking up training costs. He pointed out strategies such as profit sharing and legitimizing employee experience that have been successful at retaining employees.

Since each cannabis company is unique in its internal dynamics, players such as Cannabis Strategic Ventures Inc. (OTC: NUGS) are likely to have their own mechanisms of attracting and retaining employees, including budtenders, who are in high demand within the industry.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Swiss Government to Launch Trial Cannabis Sales Program

Switzerland is set to become the first nation in Europe to launch a marijuana sales pilot program. The program, called Weed Care, will help study the effects of the legalization of marijuana. It will be launched officially on Sept. 15, 2022, and will run until March 2025.

Weed Care involves 370 participants based in Basel, the third most populous city in the country. All participants involved in the program reside in the city, are aged 18 and above, and are already consumers of cannabis. Throughout the study period, every participant will undergo regular assessments of their mental and physical health as well as their marijuana consumption behavior.

The country’s Federal Office of Public Health stated that the pilot program was aimed at increasing knowledge of the disadvantages and advantages of controlled access to marijuana and would offer a scientific basis to legalize adult-use marijuana in Switzerland.

The Federal Office of Public Health authorized the marijuana sales pilot program on April 19, 2022. The program will be conducted jointly by the University of Basel, the Department of Health of the Basel-Stadt Canton and the University Psychiatric Clinics. Basel health department’s medical director, Lukas Engelberger, stated that the pilot project was the first in the country, highlighting that prohibition hadn’t caused a drop in consumption, which warranted the need to test new regulatory models.

In an interview, Regine Steinauer, the addiction department head at Basel University, stated that the researchers were focused on finding out whether consumption changed, but they would also look into any physical and mental health changes observed when marijuana was consumed.

After showing their IDs, the study’s participants will be able to purchase two types of hashish-based products and four types of marijuana products from the pharmacies taking part in the study. The pharmacies will sell marijuana-based products based on the price determined by the illicit market, which is between $8 and $12. Products that contain different levels of THC will be produced by Pure Production, which is based in Switzerland.

Levels of THC in hashish products vary between 13%—20% while dried flowers contain a THC level between 5%—7%.

It should be noted that the country’s law prohibits the possession of more than 10 grams of marijuana, which limits study participants to purchasing no more than 10 grams of cannabis products in pharmacies. The law also doesn’t allow the public consumption of cannabis, so participants will have to consume the products in private locations.

When the pilot project registers success and the government fully opens a regulated market for cannabis, entities that have an interest in playing at an international level, such as Flora Growth Corp. (NASDAQ: FLGC), could find themselves with a window to further penetrate the European market.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – AROYA Expands Cutting-Edge Platform to Add Automated Irrigation Control

AROYA, a METER Group company, today unveiled Automated Irrigation Control as the latest crop steering enhancement to its industry leading AROYA Cannabis Production Platform. Crop steering technology enables operators of all sizes to bring out the best features of each cultivar. “Many craft farmers remain committed to their tried-and-true manual methods, like physically pouring run-off into milliliter cups, taking notes and running tests by hand,” said AROYA CEO Scott Campbell. “And to their credit, these purists are having success. However, for the independent purists, failing to embrace cultivation and production technology will be their demise. In addition to competition from larger operators, many smaller outfits have gone all-in with crop steering, advanced drying and analytics… Scalability through repeatable processes that ensure consistent outputs is the quintessential advantage for successful cannabis cultivation. With AROYA’s new offering, growers can replicate irrigation schedules and attach them to harvest groups/recipes without having to start from zero with each new grow cycle.”

To view the full press release, visit https://cnw.fm/KFku6

About AROYA

AROYA is a cannabis production platform that combines industry leading hardware and software to help cultivators increase yield, scale operations and achieve consistent quality. Based in Pullman, Washington, and a division of METER Group Inc., AROYA optimizes and demystifies the entire cannabis production process from seed to package. For additional information, please visit www.AROYA.io.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Oklahoma Voters May Not Decide Fate of Cannabis Measure Despite Ample Signature Submission

Voters in Oklahoma may not get the chance to vote on cannabis legalization during the upcoming November ballot even though reform activists behind a cannabis legalization measure collected enough signatures. Even though state officials confirmed that activists had reached the signature threshold, the campaign still needs to fulfill a few formalities before the deadline for printing voting materials passes.

Last month, the Oklahomans for Sensible Marijuana Laws (OSML) campaign announced that it had submitted more than 164,000 signatures to the Oklahoma secretary of state’s office, surpassing the signature threshold that was needed by more than 50,000 signatures. The campaign’s initiative would have allowed Oklahomans aged 21 and older to purchase and possess up to an ounce of cannabis. The legislation would also have allowed adults to cultivate a limited number of cannabis plants at home for personal use.

However, with the state deadline for printing voting material fast approaching, the fate of the initiative now hangs in the balance. Backed by New Approach PAC, the campaign will now take its initiative to the Supreme Court for review. If the court signs off on the signature count, the public will have 10 days to challenge the petitions’ validity.

According to Election Board Secretary Paul Ziriax, however, Aug. 29, 2022, is the deadline to officially certify measures for the November ballot. Furthermore, officials would have had to receive a gubernatorial proclamation of the ballot status by 5 p.m. on Friday, Aug. 26, 2022.  Ziriax said in a June letter that the “practical deadline” is meant to give county election boards enough time to prepare ballots to meet the 34-day deadline for sending absentee ballots to military voters who are overseas.

The OSML campaign bristled at the deadline’s introduction, calling it artificial and asking the Supreme Court to ensure that voters will be able to vote on the cannabis legalization measure on the November ballot. Oklahomans are more than ready for the creation of sensible marijuana laws rather than blanket criminalization, the campaign stated in a Twitter post, and the insane number of signatures it managed to collect are proof of this sentiment.

Observers believe the signature verification process has taken longer than usual this year because the secretary of state’s office outsourced the verification process to a third-party company, Western Petition Systems, rather than handling the process internally. This administrative delay has taken twice as long as when the secretary of state verified the signatures itself; the delay could prevent the bill from making it to the November ballot, Oklahoma Watch says.

The uncertainty surrounding whether or not Oklahoma voters will be able to make their voices heard regarding the proposed change in marijuana policy in the state is indicative of the huge obstacles that the marijuana industry and ancillary companies such as Advanced Container Technologies Inc. (OTC: ACTX) have to face in order to serve the customers who need their products, such as the equipment used in vertical cultivation indoors.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.